{"id":71492,"date":"2026-05-20T10:15:00","date_gmt":"2026-05-20T10:15:00","guid":{"rendered":"https:\/\/medsbase.com\/snap-8-acetyl-octapeptide-3\/"},"modified":"2026-05-21T07:14:09","modified_gmt":"2026-05-21T07:14:09","slug":"snap-8-acetyl-octapeptide-3","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/snap-8-acetyl-octapeptide-3\/","title":{"rendered":"SNAP-8 (Acetyl Octapeptide-3) \u2014 Research Grade"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is SNAP-8 (Acetyl Octapeptide-3)?<\/h3>\n

SNAP-8<\/strong> (also called Acetyl Octapeptide-3<\/strong> of Acetyl Glutamyl Octapeptide-3<\/strong>, CAS 868844-74-0) is a synthetic 8-amino-acid SNAP-25-mimetic peptide<\/strong>: Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-OH (Ac-EEMQRRADA-OH). Molecular formula C40<\/sub>H68<\/sub>N14<\/sub>O17<\/sub>S, MW 1,078.13 g\/mol. SNAP-8 mimics the N-terminal end of SNAP-25<\/strong> \u2014 a SNARE-complex protein required for neurotransmitter exocytosis at the neuromuscular junction (and the molecular target of botulinum toxin \/ Botox). The mimetic competes with native SNAP-25 for binding to the SNARE complex, reducing assembly of the vesicle-fusion machinery and producing a “topical botulinum-like” effect<\/strong> \u2014 reduced acetylcholine release at neuromuscular junctions. Originally developed and patented by Lipotec (Spain); widely cited in cosmeceutical research and as a topical-application alternative to injectable botulinum toxin. For laboratory research use only.<\/p>\n<\/div>\n

Wat u krijgt bij MedsBase:<\/strong> Lyophilized \u226599% HPLC-verified SNAP-8 (Acetyl Octapeptide-3) \u00b7 COA available on request \u00b7 Discreet temperature-stable packaging \u00b7 Worldwide research-supply courier \u00b7 1,400+ verified klantbeoordelingen<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specificatie<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
Compound Class<\/strong><\/td>\nSynthetic 8-aa SNAP-25-mimetic peptide; SNARE-complex inhibitor; cosmeceutical \/ topical-application research peptide<\/td>\n<\/tr>\n
Chemical Name<\/strong><\/td>\nAcetyl Octapeptide-3 (synonyms: SNAP-8, Acetyl Glutamyl Octapeptide-3, Argireline-NG; INCI: Acetyl Octapeptide-3)<\/td>\n<\/tr>\n
CAS-nummer<\/strong><\/td>\n868844-74-0<\/td>\n<\/tr>\n
Sequentie<\/strong><\/td>\nAcetyl-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-OH (Ac-EEMQRRADA-OH; 8 amino acids; N-terminal acetylation for stability)<\/td>\n<\/tr>\n
Molecular Formula \/ MW<\/strong><\/td>\nC40<\/sub>H68<\/sub>N14<\/sub>O17<\/sub>S; MW 1,078.13 g\/mol<\/td>\n<\/tr>\n
Werkingsmechanisme<\/strong><\/td>\nMimics the N-terminal of SNAP-25<\/strong>, a SNARE-complex protein required for neurotransmitter vesicle docking and fusion at the synapse. SNAP-8 competes with native SNAP-25 for binding to the SNARE complex (with syntaxin and VAMP \/ synaptobrevin), reducing functional SNARE assembly and inhibiting acetylcholine release at neuromuscular junctions. The result is “topical botulinum-like” reduction of muscle-fibre activation, primarily applied to facial-expression muscles in cosmeceutical contexts.<\/td>\n<\/tr>\n
SNAP-8 vs Argireline (Acetyl Hexapeptide-8)<\/strong><\/td>\nSNAP-8 is the 8-residue extension of Argireline (Acetyl Hexapeptide-8, 6-aa). The additional two N-terminal glutamate residues provide enhanced SNARE-complex binding affinity (~2-3\u00d7 more active than Argireline per Lipotec patent data) and improved skin-penetration kinetics in topical applications.<\/td>\n<\/tr>\n
Form \/ Purity \/ Storage<\/strong><\/td>\nLyophilized white-to-off-white powder; \u226599% HPLC, COA on request. Store at 2\u20138 \u00b0C (short-term) or \u221220 \u00b0C (long-term, \u226536 months). Reconstituted aqueous: 2\u20138 \u00b0C, use within 30 days.<\/td>\n<\/tr>\n
Onderzoeksgebruik<\/strong><\/td>\nFor laboratory research use only. Not for human or veterinary diagnostic or therapeutic use. Used in topical-cosmetic and skin-penetration research; not on the WADA Prohibited List.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Mechanism of Action \u2014 SNARE Complex Inhibition<\/h2>\n

SNAP-25 is one of three core proteins of the neuronal SNARE complex (alongside syntaxin-1 and synaptobrevin\/VAMP-2). The SNARE complex catalyses the fusion of synaptic vesicles with the presynaptic plasma membrane \u2014 releasing the vesicular content (acetylcholine at neuromuscular junctions, other neurotransmitters at central synapses) into the synaptic cleft. SNAP-25 is also the molecular target cleaved by botulinum toxin types A and E \u2014 explaining how Botox produces its neuromuscular-paralysis effect.<\/p>\n

SNAP-8 \/ Acetyl Octapeptide-3 mimics the first 8 residues of SNAP-25’s N-terminal helix. By binding to the SNARE-complex assembly site, SNAP-8 competes with intact native SNAP-25 \u2014 partially reducing functional SNARE-complex formation and therefore reducing the amount of acetylcholine released per nerve impulse. The net consequence at facial-expression muscles is reduced contraction amplitude and reduced expression-line formation \u2014 the basis for SNAP-8’s cosmeceutical use as a topical anti-wrinkle peptide.<\/p>\n

Gepubliceerde onderzoeksapplicaties<\/h2>\n